Contract manufacturing services agreement signed with Yourgene Health Plc Additional manufacturing capacity to support demand for Novacyt’s COVID-19 diagnostic test

Paris, France and Camberley, UK – 25 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the notification on 20 March 2020, the Company has signed an agreement for certain contract manufacturing services with Yourgene Health Plc (“Yourgene”) (AIM: YGEN), an international molecular diagnostics group.

Visit Page

US FDA Emergency Use Authorization for COVID-19 diagnostic test COVID-19 RUO test receives approval in Indonesia

Paris, France and Camberley, UK – 23 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to announce that the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its COVID-19 test. As a result, hospitals and laboratories in the US will

Visit Page

Coronavirus test update Significant increase in demand Further expansion of manufacturing capacity

Paris, France and Camberley, UK – 20 March 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, is pleased to provide an update regarding the novel coronavirus (COVID-19) test developed by Primerdesign, its molecular diagnostics division based in the UK. http://novacyt.com/wp-content/uploads/2020/03/Novacyt-Covid-19-test-update-ENGLISH-20.03.20-Final.pdf

Visit Page